Cargando…

A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures

Objective: We assessed the efficacy, safety, and tolerability of cannabidivarin (CBDV) as add-on therapy in adults with inadequately controlled focal seizures. Materials and Methods: One hundred and sixty-two participants (CBDV n=81; placebo n=81) were enrolled. After a 4-week baseline, participants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brodie, Martin J., Czapinski, Piotr, Pazdera, Ladislav, Sander, Josemir W., Toledo, Manuel, Napoles, Mariana, Sahebkar, Farhad, Schreiber, Ashley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713263/ https://www.ncbi.nlm.nih.gov/pubmed/33998885 http://dx.doi.org/10.1089/can.2020.0075

Ejemplares similares

Long‐term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program
por: Sander, Josemir W., et al.
Publicado: (2021)

The burden of epilepsy and unmet need in people with focal seizures
por: Ioannou, Persefoni, et al.
Publicado: (2022)

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial
por: Thiele, Elizabeth A., et al.
Publicado: (2020)

First add‐on perampanel for focal‐onset seizures: An open‐label, prospective study
por: Kim, Ji Hyun, et al.
Publicado: (2019)

Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures
por: Fogarasi, Andras, et al.
Publicado: (2020)

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
por: Villar, Miriam Méndez-del, et al.
Publicado: (2017)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
por: Pazdera, Ladislav, et al.
Publicado: (2021)

Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study
por: Jacobson, Mercedes P, et al.
Publicado: (2015)

Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression
por: Amada, Naoki, et al.
Publicado: (2013)

Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin
por: Morano, Alessandra, et al.
Publicado: (2016)

Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
por: Stone, Nicole L., et al.
Publicado: (2021)

Comparative assessment of antimicrobial, antiradical and cytotoxic activities of cannabidiol and its propyl analogue cannabidivarin
por: Russo, Chiara, et al.
Publicado: (2021)

Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid against Multidrug-Resistant Neisseria gonorrhoeae
por: Yang, Fan, et al.
Publicado: (2022)

Brivaracetam: a novel antiepileptic drug for focal-onset seizures
por: Stephen, Linda J., et al.
Publicado: (2017)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study
por: Lattanzi, Simona, et al.
Publicado: (2022)

Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin
por: Saito, Daisuke, et al.
Publicado: (2017)

Effects of Evogliptin as Add on in Type 2 Diabetes (T2DM) Subjects Inadequately Controlled With Metformin and Glimepiride Combination
por: Guha, Shaibal
Publicado: (2021)

Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases
por: Berardis, Domenico De, et al.
Publicado: (2021)

Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial
por: Hurley, Ellen N., et al.
Publicado: (2022)

Neural excitatory rebound induced by valproic acid may predict its inadequate control of seizures
por: Zou, Xiang, et al.
Publicado: (2022)

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Controllable yawning expressed as focal seizures of frontal lobe epilepsy
por: Wasade, Vibhangini S., et al.
Publicado: (2016)

Cannabidivarin alleviates neuroinflammation by targeting TLR4 co-receptor MD2 and improves morphine-mediated analgesia
por: Wang, Xue, et al.
Publicado: (2022)

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
por: Han, Kyung‐Ah, et al.
Publicado: (2018)

Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2022)

Cardiac arrhythmias during or after epileptic seizures
por: van der Lende, Marije, et al.
Publicado: (2016)

Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells
por: Russo, Chiara, et al.
Publicado: (2018)

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Verbal fluency functional magnetic resonance imaging detects anti‐seizure effects and affective side effects of perampanel in people with focal epilepsy
por: Xiao, Fenglai, et al.
Publicado: (2023)

Oral Levetiracetam as Add-On Therapy in Refractory Neonatal Seizures
por: MOLLAMOHAMMADI, Mohsen, et al.
Publicado: (2018)

Pooled efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Data from four double‐blind placebo‐controlled pivotal phase III clinical studies
por: Elger, Christian, et al.
Publicado: (2017)

Unusual seizure evolution: Focal-general-focal-general
por: Smelick, Christopher, et al.
Publicado: (2018)

Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial
por: Blonde, Lawrence, et al.
Publicado: (2020)

Computational modelling of micro-seizures and focal seizure onset
por: Wang, Yujiang, et al.
Publicado: (2013)

Arousal and Consciousness in Focal Seizures
por: Blumenfeld, Hal
Publicado: (2021)

Adaptation and Inhibition Control Pathological Synchronization in a Model of Focal Epileptic Seizure
por: Buchin, Anatoly, et al.
Publicado: (2018)

Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin
por: Pretzsch, Charlotte M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bjrjhr0vol2n9suidi9ljeka7r